| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M G Caporali, A Scotti de Carolis, P Popol. N-ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits. European journal of pharmacology. vol 223. issue 1. 1993-02-05. PMID:1478256. |
a pattern of perioral dyskinesia was induced in adult male rabbits by concomitant stimulation of dopamine d1 receptors (skf 38393) and blockade of dopamine d2 receptors (sulpiride). |
1993-02-05 |
2023-08-11 |
Not clear |
| M G Caporali, A Scotti de Carolis, P Popol. N-ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits. European journal of pharmacology. vol 223. issue 1. 1993-02-05. PMID:1478256. |
the present results confirm that perioral dyskinesia is dependent on the activation of dopamine d1 receptors. |
1993-02-05 |
2023-08-11 |
Not clear |
| M G Caporali, A Scotti de Carolis, P Popol. N-ethyl-carboxamide adenosine inhibits perioral dyskinesias induced by sulpiride + SKF 38393 in rabbits. European journal of pharmacology. vol 223. issue 1. 1993-02-05. PMID:1478256. |
they also show that, in order to induce perioral dyskinesia in rabbits, a concomitant blockade of dopamine d2 receptors is required. |
1993-02-05 |
2023-08-11 |
Not clear |
| F Baronti, M M Mouradian, T L Davis, M Giuffra, G Brughitta, K E Conant, T N Chas. Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's disease. Annals of neurology. vol 32. issue 6. 1993-01-25. PMID:1471868. |
these results lend further support to the view that continuous dopamine replacement ameliorates motor fluctuations and peak-dose dyskinesias that complicate standard levodopa regimens. |
1993-01-25 |
2023-08-11 |
Not clear |
| H Przuntek, D Welzel, E Blümner, W Danielczyk, H Letzel, H J Kaiser, P H Kraus, P Riederer, D Schwarzmann, H Wol. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. European journal of clinical pharmacology. vol 43. issue 4. 1992-12-31. PMID:1451713. |
the long-term benefit of therapy is limited by adverse effects, such as dyskinesia and on-off phenomena, which can be mitigated by the concomitant administration of dopamine agonists, such as bromocriptine. |
1992-12-31 |
2023-08-11 |
Not clear |
| G A Donnan, D G Woodhouse, S J Kaczmarczyk, J E Holder, G Paxinos, P J Chilco, A J Churchyard, R M Kalnins, G C Fabinyi, F A Mendelsoh. Evidence for plasticity of the dopaminergic system in parkinsonism. Molecular neurobiology. vol 5. issue 2-4. 1992-09-23. PMID:1823144. |
although some elements of the compensatory mechanism of dopamine plasticity may be deleterious, such as dyskinesias owing to dopamine receptor supersensitivity, the overall effect of delay and minimization of the clinical expression of disease is advantageous. |
1992-09-23 |
2023-08-11 |
human |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. |
1992-08-19 |
2023-08-11 |
monkey |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
the neural mechanisms that underlie both the anti-parkinsonian effects of dopamine agonists and dopamine agonist-induced dyskinesia were studied in parkinsonian primates, using the regional brain uptake of [3h]2-deoxyglucose (2-dg). |
1992-08-19 |
2023-08-11 |
monkey |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
some of the animals received chronic dopamine replacement therapy for at least 3 mths, which resulted in the appearance of peak-dose dyskinesia. |
1992-08-19 |
2023-08-11 |
monkey |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
the remaining animals spent an equivalent period of time relatively unexposed to dopaminergic agents, receiving only therapeutic doses, and at no time showed any signs of dopamine agonist-induced dyskinesia. |
1992-08-19 |
2023-08-11 |
monkey |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
the 2-dg metabolic mapping technique was applied to all of these animals shortly following the administration of a dose of dopamine agonist which was sufficient to alleviate their parkinsonian symptoms and to induce dyskinesia in those prone to this complication. |
1992-08-19 |
2023-08-11 |
monkey |
| I J Mitchell, S Boyce, M A Sambrook, A R Crossma. A 2-deoxyglucose study of the effects of dopamine agonists on the parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain : a journal of neurology. vol 115 ( Pt 3). 1992-08-19. PMID:1628204. |
the remaining animals had their parkinsonism reversed by the dopamine agonist but showed dyskinesia at peak dose. |
1992-08-19 |
2023-08-11 |
monkey |
| F Baronti, M M Mouradian, K E Conant, M Giuffra, G Brughitta, T N Chas. Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology. vol 42. issue 6. 1992-07-13. PMID:1351273. |
partial dopamine agonist therapy of levodopa-induced dyskinesias. |
1992-07-13 |
2023-08-11 |
Not clear |
| M R Luquin, O Scipioni, J Vaamonde, O Gershanik, J A Obes. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Movement disorders : official journal of the Movement Disorder Society. vol 7. issue 2. 1992-06-12. PMID:1350058. |
dopamine agonists enhanced "on" dyskinesias and markedly reduced or abolished "off" period dystonia and dd. |
1992-06-12 |
2023-08-11 |
Not clear |
| U D Madej. [The dopamine agonist, lisuride, in the therapy of Parkinson disease]. Acta histochemica. Supplementband. vol 42. 1992-06-12. PMID:1584973. |
the early combination of low doses of levodopa with a dopamine agonist as lisuride improves the symptoms of parkinson's disease as much as a monotherapy but prevents the development of fluctuations in disability and dyskinesias at the same time. |
1992-06-12 |
2023-08-11 |
Not clear |
| H A Robertso. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques. vol 19. issue 1 Suppl. 1992-06-02. PMID:1349263. |
synergistic interactions of d1- and d2-selective dopamine agonists in animal models for parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias. |
1992-06-02 |
2023-08-11 |
rat |
| W P Spooren, P A Piosik, A R Cool. Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats. European journal of pharmacology. vol 204. issue 2. 1992-05-14. PMID:1839622. |
dopamine d1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats. |
1992-05-14 |
2023-08-11 |
Not clear |
| W P Spooren, P A Piosik, A R Cool. Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats. European journal of pharmacology. vol 204. issue 2. 1992-05-14. PMID:1839622. |
the possible role of dopamine d1 receptors in the sub-commissural part of the globus pallidus in the induction of oro-facial dyskinesia was studied in cats. |
1992-05-14 |
2023-08-11 |
Not clear |
| W P Spooren, P A Piosik, A R Cool. Dopamine D1 receptors in the sub-commissural part of the globus pallidus and their role in oro-facial dyskinesia in cats. European journal of pharmacology. vol 204. issue 2. 1992-05-14. PMID:1839622. |
the present results thus clearly indicate that dopamine d1 receptors within the sub-commissural part of the globus pallidus are involved in mediating oro-facial dyskinesia in cats. |
1992-05-14 |
2023-08-11 |
Not clear |
| S Ruggieri, F Stocchi, F Baronti, F Viselli, R Horowski, C Lucarelli, A Agnol. Antagonist effect of terguride in Parkinson's disease. Clinical neuropharmacology. vol 14. issue 5. 1992-01-10. PMID:1683813. |
further studies using a wider dose titration are required to evaluate the possible role of dopamine partial agonists in the therapy of levodopa-induced dyskinesias. |
1992-01-10 |
2023-08-11 |
Not clear |